[1]
|
N. M. Van Mello, S. R. Pillemer, P. P. Tak, et al., “B Cell MALT Lymphoma Diagnosed by Labial Minor Salivarygland Biopsy in Patients Screened for Sjo¨Gren’s Syndrome,” Annals of Rheumatic Disease, Vol. 64, No. 3, 2005, pp. 471-473. doi:10.1136/ard.2004.022707
|
[2]
|
R. Ionescu, et al., “Esentialul in Reumatologie,” Cap.19, 2nd Revised Edition, Daniela Opris, Amaltea, Bucharest, 2007, pp. 270-279.
|
[3]
|
B. Royer , D. C. Hatem and J. Sibilia, “Lymphomas in Patients with Sjogren’s Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated with Viruses,” Blood, 15, Vol. 90, No. 2, 1997, pp. 766-775.
|
[4]
|
A. V. Miller, S. K. M. Ranatunga, M. L. Francis, et al., Medscape Reference (Durgs, Diseases &Procedures), Last Updated 31 October 2011.
|
[5]
|
M. Garcia Carrasco, S. Fuentes Alexandro and R. O. Escarcega, “Pathophysiology of Sjogren’s Syndrome,” Archives of Medical Research, Vol. 37, No. 8, 2006, pp. 921-932. doi:10.1016/j.arcmed.2006.08.002
|
[6]
|
J. Maggie, “A Short Review of the Pathogenesis of Sjogren Syndrome,” Larche Autoimmunity Reviews, Vol. 5, No. 2, 2006, pp. 132-135.
|
[7]
|
P. N. Nikolay and G. I. Gabor, “Pathogenesis of Sjogren’s Syndrome,” Current Opinion in Rheumatology, Vol. 21, No. 5, 2009, pp. 465-470.
|
[8]
|
C. Vitali, S. Bombaridieri. R. Jonsson, et al., “Classification Criteria for Sjogren’s Syndrome: A Revised Version of the European Criteria Proposed by the American-European Consensus Group,” Annals of Rheumatic Disease, Vol. 61, No. 6, 2002, pp. 554-558.
doi:10.1136/ard.61.6.554
|
[9]
|
P. B. Zeron, M. Ramos-Casals, A. Bove., et al., Predicting Adverse Outcomes in Primary Sjogren’s Syndrome: Identification of Prognostic Factors,” Rheumatology, Vol. 46, No. 8, 2007, pp. 1359-1362.
|
[10]
|
Y. Masaki and S. Sugai, “Lymphoproliferative Disorders in Sjogren’s Syndrome,” Autoimmunity Reviews, Vol. 3, No. 3, 2004, pp. 175-182.
|